Immunovia AB (SE:IMMNOV)
:IMMNOV
IMMNOV Stock Chart & Stats
kr0.23
-kr0.02(-4.98%)
At close: 4:00 PM EST
kr0.23
-kr0.02(-4.98%)
Day’s Range― - ―
52-Week Rangekr0.15 - kr0.75
Previous CloseN/A
Volume868.16K
Average Volume (3M)5.10M
Market Cap
kr132.78M
Enterprise Value-kr8.99M
Total Cash (Recent Filing)kr77.46M
Total Debt (Recent Filing)kr857.00K
Price to Earnings (P/E)―
Beta0.07
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding672,666,900
10 Day Avg. Volume6,199,351
30 Day Avg. Volume5,096,607
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)114.10
P/FCF Ratio-1.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)kr8.00M
Bulls Say, Bears Say
Bulls Say
Scientific Validation And VisibilityMultiple peer‑reviewed publications, repeated podium presentations and an award (CLARITI best of DDW) provide durable clinical credibility. This reduces adoption friction with clinicians, supports payer engagement and underpins long‑term uptake and guideline consideration across surveillance centers.
Established Medicare Price And Billing CodeHaving an established Medicare price and billing code is a structural advantage: it sets an explicit per‑test reimbursement benchmark, streamlines billing when coverage is granted, and materially improves revenue visibility per test versus products lacking an assigned code and fee.
Funded Launch With Improved Cost DisciplineA successful rights issue plus demonstrable cost reductions create a stronger near‑term funding base and show management prioritizes efficiency. This reduces immediate dilution risk and buys time to execute commercial rollout and registry data collection required for durable reimbursement outcomes.
Bears Say
Very Small And Declining Revenue BaseA tiny, shrinking revenue base hampers the company's ability to scale fixed costs and demonstrate a sustainable business model. Without a steady and growing test volume, operating leverage remains negative and profitability will be difficult to achieve over the medium term.
Persistent Negative Cash Flow And External Funding RelianceSustained negative operating and free cash flow forces reliance on external capital, increasing dilution and execution risk. If capital markets tighten or future raises are constrained, the company may face impaired ability to complete commercialization and registry studies critical to long‑term revenue realization.
Payer Coverage Not Yet SecuredWithout formal payer coverage, the established Medicare price cannot be broadly realized and commercial adoption will remain limited. Coverage timing is uncertain and directly affects durable revenue scaling, collections and the incentives for providers to integrate testing into care pathways.
Immunovia AB News
IMMNOV FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was kr0.15 and its highest was kr0.75 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is kr132.78M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is May 07, 2026 which is in 28 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Feb 24, 2026. The company reported -kr0.033 earnings per share for the quarter, beating the consensus estimate of -kr0.039 by kr0.006.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -kr0.033 in its last earnings report, beating expectations of -kr0.039. Following the earnings report the stock price went down -13.333%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in SE:IMMNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
IMMNOV Company Deck
IMMNOV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful commercial, scientific and reimbursement progress: a successful product launch, strong clinical publications and podium presence, an awarded Medicare pricing of USD 897, state approvals in 48 states, targeted hiring of account managers, and a completed rights issue that improved cash position. However, near-term revenue remains limited, full payer coverage is not yet granted, cash runway extends only to Q3 2026 without additional capital, and realized per-test pricing and collections are still uncertain. The company emphasized disciplined spending, planned clinical utility data collection (including a 400-patient registry) and a mid-2026 Medicare submission with rolling data updates to mitigate coverage risk.View all SE:IMMNOV earnings summariesTechnical Analysis
Alligator Bioscience AB
―
Prostatype Genomics AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Klaria Pharma Holding AB
―